Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
Intraday
Monitor top intraday performers in real time
ETF Screener
Get the best of Mutual Funds and flexibility of Stocks
IPO
Track upcoming and ongoing IPOs
MTFs
Buy now, pay later
Stock Screener
Filter based on RSI, PE ratio and more
Stock Events
Dividends, bonus, buybacks and more
Demat Account
Begin your stock market journey
Share Market Today
Live news updates from stock market
F&O
Trade in Futures & Options
Trade in F&O using the terminal. View charts, indicators, track your orders , P&L and watchlists in a single space
Indices
Track markets across the globe
Terminal
Track charts, orders, positions, watchlists in one place
Option chain
Analyse chains, view payoffs, create baskets
Pledge
Get extra balance for trading
Commodities
Trade in Crude Oil, Gold, Silver and more
API trading
Set up and execute trades through our API
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
Mutual Fund Houses
Know about AMCs, funds, fund managers
NFO’s
Track all active NFOs in one place
Mutual Funds by Groww
Mutual funds by Groww designed for your investment goals
Start SIP
Build long-term wealth through disciplined monthly investing.
Mutual Funds screener
Filter funds based on risk, fund size and more
Track Funds
Import funds and track all investments in a single place
Compare Funds
More
SIP calculator
Estimate returns on a SIP
Brokerage calculator
Estimate charges for your trade/investment
Margin calculator
Estimate balance needed to buy/sell a stock
SWP calculator
Returns on your systematic withdrawal plan
Pricing
Brokerage and charges on Groww
Blog
Manage alerts
Active alerts for Lupin
Add new alert
LUPIN •
NSE
Lupin
₹2,314.90
-42.40 (1.80%)
1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Terminal
Create Stock SIP
Automate your investments in this
Overview
Technicals
News
Events
F&O
ScoutQuest •
17 hours ago
Delaware Court upheld Astellas Pharma's Myrbetriq patents, blocking Ascent Pharma's generic until 2030. This benefits Lupin and Zydus, who have already launched their generic versions.
CNBC TV18 •
5 days ago
Lupin CFO highlights freight cost hikes due to West Asia conflict affecting pharma sector. Lupin targets FY26 EBITDA margins of 26-27% and $1B US sales amid growth in India diabetes market.
Livesquawk •
5 days ago
Lupin indicates rising oil prices may increase solvent costs, affecting production. Profitability could be impacted due to higher production expenses from oil price hikes.
Livesquawk •
5 days ago
Lupin reports cargo movement disruptions due to container delays at European and Middle Eastern ports.
Business Standard •
5 days ago
Lupin falls 1.8% to Rs 2,301.25 after US FDA issues Form 483. Ankleshwar facility inspection yields 2 observations; Lupin to respond promptly.
Livesquawk •
5 days ago
Morgan Stanley maintains Equal-Weight on Lupin with Rs 2,386 TP, citing manageable USFDA compliance risks. Lupin is expected to deliver strong FY26 earnings growth, marking its second consecutive year of growth.
BSE •
6 days ago
Lupin's Ankleshwar facility inspection by U.S. FDA concluded with Form 483, noting two observations. Lupin commits to addressing observations and maintaining CGMP standards across facilities.
CNBC TV 18 •
1 week ago
Lupin shares hit 52-week high, gaining 11% YTD, outperforming Nifty Pharma's 1.2% rise. Q3 revenue surged 28% YoY to ₹7,167 crore; US sales reached record $350M, aiding growth forecasts.
BSE •
2 weeks ago
Lupin Ltd updates on Nanomi B.V.'s acquisition of VISUfarma B.V., Netherlands. Transaction completion delayed to April 2026, pending closing condition fulfillment.
ScoutQuest •
2 weeks ago
Lupin received US FDA EIR for its Goa facility, classified as VAI. VAI indicates no major violations but minor observations from Nov 10-21 inspection.